Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Beclometason (ausschl. DaFo IHP), ATC R03BA01 für die Zeit 01.05.26-30.04.28

Section 130a, paragraph 8 of the German Social Code (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures takes place in accordance with the regulations of Part 4 of the German Competition Act (GWB) by the DAK-Gesundheit. For the pharmaceuticals to be specified by the bidder in Appendix 2 to the contract for the aforementioned substance Beclometason (exclusively in the IHP formulation), ATC R03BA01, the DAK-Gesundheit intends to conclude pharmaceutical discount agreements with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount agreements. A discount contract under the authorisation model for the aforementioned substance comes into force for the first time on 01.05.2026 and ends on 30.04.2028. It ends automatically with the entry into force of the exclusive contract, regardless.